Plate Nº 96 · recorded November 17, 2026

Health & Medicine ResearchReported finding

Drug That Destroys Testosterone Receptors Slashes Prostate Cancer Marker

An experimental drug that destroys testosterone receptors halved PSA levels in nearly 60% of men with T878/H875 mutations in a phase I/II trial.

By Priya Raman3 min read650 words

In brief

  1. Nearly 60 percent of patients with T878/H875 receptor mutations saw PSA levels drop by at least half, versus 3-4 percent with other gene profiles.
  2. Median time before cancer worsened or death was 11 months in the mutation group versus 4-5 months in others.
  3. The trial had no control group, and results do not prove longer survival or tumor shrinkage.
  4. Arvinas is now prioritizing a similar drug, luxdegalutamide (ARV-766), with a trial completing in May 2027.
  5. Findings were published in the Journal of Clinical Oncology.
Experimental Drug That Destroys Testosterone Receptors Shows Promise Against Prostate Cancer
Plate Nº 96Experimental Drug That Destroys Testosterone Receptors Shows Promise Against Prostate Cancer — AI-generated

Nearly 60 percent of men with a specific mutation in their tumor's testosterone receptors saw their prostate-specific antigen levels fall by at least half after taking an experimental drug, according to results from a combined phase I and phase II clinical trial published in the Journal of Clinicalology data — more precisely, the Journal of Clinical Oncology.

The oral medicine, called bavdegalutamide (also known by its research code ARV-110), is taken daily. Rather than starving tumors of testosterone, it destroys the receptors that the hormone uses to drive cancer growth.

The trial was conducted at three institutions: Massachusetts General Hospital, the Yale School of Medicine, and Arvinas, the biotechnology company that developed the drug and funded the study. Phase I established a safe dosage, and phase II tested that dosage in patients carrying different mutations in their testosterone receptors.

Why the approach matters

For nearly a century, oncologists have treated advanced prostate cancer by depriving tumors of testosterone, their main fuel. Existing therapies either suppress the hormone's production or block it from binding to and activating its receptors.

But the cancer is resourceful. It can mutate and learn to feed on different hormones, and resistance is the rule rather than the exception. The trial authors write that "approximately 20 percent – 40 percent of patients are unresponsive to these treatments and nearly all eventually develop resistance."

Bavdegalutamide represents a different strategy: eliminating the receptor itself.

"Bavdegalutamide takes your own natural protein degradation system, and it accelerates the process for the androgen receptor," explains oncologist Daniel Petrylak from Yale University. "The drug degrades the receptors for testosterone, which control prostate cancer growth."

The androgen receptor (the cellular docking protein that testosterone binds to) was the drug's target across the entire trial population.

What did the trial show?

The trial focused on patients with metastatic castration-resistant prostate cancer, or mCRPC — the stage at which the cancer has spread and no longer responds to androgen deprivation therapy (treatment that cuts off the body's testosterone supply). mCRPC is incurable and ultimately lethal, though some treatments can slow its progression and extend life.

The key findings:

  • Nearly 60 percent of participants whose tumors carried the T878/H875 mutations saw their prostate-specific antigen (PSA, a blood marker of prostate cancer activity) drop by at least half — an encouraging sign that the cancer was responding.
  • Only 3 to 4 percent of men with other gene profiles experienced the same improvement.
  • Among the 20 participants with T878/H875 mutations, it took a median of 11 months before their cancer worsened on scans or they died.
  • Among men with other genetic profiles, that figure was about 4 to 5 months.

"There was a decrease in prostate specific androgen. We also saw regressions in soft tissue lesions, and improvements in pain," says Petrylak. "These are the parameters that indicate a positive response."

What are the caveats?

Several important limitations temper the results. All participants received the experimental drug, so the trial had no traditional control group, which makes comparisons with standard treatment harder to interpret.

The results also do not necessarily mean the drug shrinks prostate tumors or that patients will live longer. The benefits were concentrated in a small subset of patients — the 20 people with the T878/H875 receptor mutations — and the response among men with other genetic profiles was minimal.

Side effects were another problem. Many participants reported nausea, fatigue, vomiting, and diarrhea.

What comes next?

The developer, Arvinas, is now prioritizing another prostate cancer drug called ARV-766 (luxdegalutamide). It uses a similar receptor-destroying mechanism but appears to produce fewer side effects.

A combined phase I/II clinical trial of luxdegalutamide is currently underway and is scheduled for completion in May 2027.

For a cancer that learns to outwit nearly every therapy aimed at it, a drug that removes the target altogether offers a promising new line of attack.

via sciencealert.com (Source)

Filed under

  • prostate-cancer
  • bavdegalutamide
  • androgen-receptors
  • clinical-trials
  • precision-medicine
Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.

476 articles

Nearby plates

« Previous articleNext article »